Use and Outcomes of Triple Antithrombotic Therapy with Non-Vitamin K Antagonists in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention

Núria Casamira, Tamara García-Camarero, J. Bruno Montoro-Ronsano, Gabriela Veiga, Bruno García Del Blanco, José María De La Torre, Blanca Gordon, David García-Dorado, Antonia Sambola

Research output: Contribution to journalArticleResearch

2 Citations (Scopus)

Abstract

© 2019 Background: Triple antithrombotic therapy (TT) is recommended for patients with nonvalvular atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI). However, there is a lack of comparative data in a real-world clinical setting between non-vitamin K antagonist oral anticoagulants (NOAC) and vitamin K antagonists (VKA). The aim of this study was to compare the safety and efficacy of TT with NOAC or VKA after PCI in patients with AF at 1-year of follow-up. Materials and Methods: This was an observational retrospective study in 2 tertiary care hospitals during 2013-2016. Patients with indication for anticoagulation due to AF from an initial registry of 5,269 patients undergoing PCI were identified. Safety primary endpoint was the occurrence of major bleeding events as defined by Bleeding Academic Consortium (BARC ≥ 3). The primary efficacy endpoint was defined as major adverse cardiovascular events (MACE). Results: A total of 187 consecutive patients on TT were identified: 45.4% of were discharged on NOAC and 54.6% on VKA. Patients who received VKA presented more comorbidities and had a higher bleeding risk than those who received NOACs. Major bleeding events occurred in 17 patients (9%), with a higher rate in the VKA group (3.5% vs. 13% confidence interval, 0.19-0.86, P = 0.02). There were no differences in the rates of major adverse cardiovascular events, stroke or net clinical benefit. Conclusions: In this real-world study, patients with AF undergoing PCI treated on NOAC-based TT showed lower bleeding rates than those on VKA, with a lower rate of major bleeding events, while efficacy was similar between groups.
Original languageEnglish
Pages (from-to)95-103
JournalAmerican Journal of the Medical Sciences
Volume358
DOIs
Publication statusPublished - 1 Aug 2019

Keywords

  • Anticoagulant
  • Atrial fibrillation
  • Bleeding
  • Non-vitamin K antagonist oral anticoagulants
  • Percutaneous Coronary Intervention

Fingerprint Dive into the research topics of 'Use and Outcomes of Triple Antithrombotic Therapy with Non-Vitamin K Antagonists in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention'. Together they form a unique fingerprint.

Cite this